Executive summary of clinical practice guideline for the management of invasive diseases caused by Aspergillus: 2018 Update by the GEMICOMED-SEIMC/REIPI

Carolina Garcia-Vidal, Ana Alastruey-Izquierdo, Manuela Aguilar-Guisado, Jordi Carratalà, Carmen Castro, Mario Fernández-Ruiz, José María Aguado, José María Fernández, Jesús Fortún, José Garnacho-Montero, Joan Gavaldà, Carlota Gudiol, Jesús Guinea, Alicia Gómez-López, Patricia Muñoz, Javier Pemán, Montserrat Rovira, Isabel Ruiz-Camps, Manuel Cuenca-Estrella

    Research output: Contribution to journalArticleResearch

    17 Citations (Scopus)

    Abstract

    © 2018 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica Aspergillus infection is a significant cause of morbi-mortality in an at-risk population. The Study Group of Fungal Infections (GEMICOMED) from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) has reviewed announcements made in invasive aspergillosis management. We have organized our recommendations in such a way as to provide a guide in resolving different clinical situations concerning the entire spectrum of invasive diseases caused by Aspergillus in various populations. Diagnostic approach, treatment and preventions strategies are outlined. It is not our aim that these guidelines supplant clinical judgment with respect to specific patients; however, it is our objective to perform a comprehensive summary of quality of care evidence for invasive aspergillosis management in different settings.
    Original languageEnglish
    Pages (from-to)535-541
    JournalEnfermedades Infecciosas y Microbiologia Clinica
    Volume37
    DOIs
    Publication statusPublished - 1 Oct 2019

    Keywords

    • Aspergillosis
    • Isavuconazole
    • Therapeutic drug monitoring
    • Treatment
    • Voriconazole

    Fingerprint

    Dive into the research topics of 'Executive summary of clinical practice guideline for the management of invasive diseases caused by Aspergillus: 2018 Update by the GEMICOMED-SEIMC/REIPI'. Together they form a unique fingerprint.

    Cite this